INDIANAPOLIS, Oct. 12, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz met co-primary endpoints as well as all major secondary endpoints in a Phase 3 study in pediatric patients with moderate to severe plaque psoriasis, demonstrating that 89 percent of patients treated with Taltz achieved a significant 75 percent improvement from baseline to Week 12 on their Psoriasis Area and Severity Index score (PASI 75) and 81 percent of patients treated with Taltz achieved a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1). Results of the study are being presented as a late-breaking oral presentation at the European Academy of Dermatology and Venereology Congress (EADV) in Madrid, Spain. Based on these positive results, Lilly plans to submit for U.S. regulatory approval for pediatric patients with moderate to severe plaque psoriasis.
"Results from our study indicate that Taltz may have the potential to clear skin and reduce itch in pediatric patients with moderate to severe plaque psoriasis," said study investigator Kim Papp, MD, PhD, Probity Medical Research, Inc., Waterloo, Ontario, Canada. "While it is estimated that up to one third of people with psoriasis first develop symptoms during childhood, there are limited medications available for pediatric patients. This study provides encouraging data supporting the potential for Taltz to become another treatment option for this patient population."
The co-primary endpoints of the study were the proportion of patients achieving a significant 75 percent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12. Key secondary endpoints included the proportion of patients achieving PASI 90, sPGA (0) and PASI 100 at Week 12, and at least a four-point improvement in Itch Numeric Rating Scale (Itch NRS 4) among patients with baseline Itch NRS 4 at Week 12, as well as PASI 75 and sPGA 0,1 at Week 4. The proportion of patients achieving 0 or 1 on the Children's Dermatology Life Quality Index (CDLQI, patients 6 to 16 years old) or DLQI (patients 17 years old) at Week 12 was also evaluated.
"We recognize that psoriasis can have a significant impact on children and adolescents, causing challenging symptoms and affecting their self-esteem and ability to connect to peers," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We're pleased to see positive results for Taltz in pediatric patients. These results build on more than five years of safety and efficacy data in adults and support the potential for Taltz in this new population, pending regulatory approvals."
A total of 201 patients aged 6 to <18 years of age with moderate to severe plaque psoriasis were randomized to receive Taltz (20 mg for <25 kg, 40 mg for 25-50 kg or 80 mg for >50 kg through Week 12, with 40 mg, 80 mg or 160 mg starting doses, respectively) or placebo. At 12 weeks, the proportion of patients achieving the co-primary endpoints was superior to placebo with statistically significant difference (P<0.001), including:
Taltz also met all major secondary endpoints in the study (P<0.001).
In this trial, the overall safety profile of Taltz was consistent with previously reported results. The Taltz safety profile has been studied across 15 clinical trials in plaque psoriasis and psoriatic arthritis, with 6,989 patients receiving Taltz, with a total exposure of 16,586 patient-years.1,2,3
INDICATIONS AND USAGE FOR TALTZTaltz is approved for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Taltz is also approved for the treatment of adults with active psoriatic arthritis and active ankylosing spondylitis.
IMPORTANT SAFETY INFORMATION FOR TALTZ
CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.
WARNINGS AND PRECAUTIONSInfectionsTaltz may increase the risk of infection. In clinical trials of patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of patients with psoriatic arthritis and ankylosing spondylitis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.
Pre-Treatment Evaluation for TuberculosisEvaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.
HypersensitivitySerious hypersensitivity reactions, including angioedema and urticaria (each 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.
Inflammatory Bowel DiseaseDuring Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease. Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz 80 mg Q2W group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than in the placebo group (0%) during clinical trials in patients with plaque psoriasis and in the Taltz Q4W group in ankylosing spondylitis trials (Crohn's disease 1.0% [2 patients], ulcerative colitis 0.5% [1 patient]) than in the placebo group (Crohn's disease 0.5% [1 patient], ulcerative colitis 0%). In the ankylosing spondylitis trials, serious events occurred in 1 patient in the Taltz group and 1 patient in the placebo group.
ImmunizationsPrior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.
ADVERSE REACTIONSMost common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, and tinea infections. Overall, the safety profiles observed in patients with psoriatic arthritis and ankylosing spondylitis were consistent with the safety profile in patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis.
Please see accompanying Prescribing Information and Medication Guide. Please see Instructions for Use included with the device.
IX HCP ISI 23AUG2019
About TaltzTaltz (ixekizumab) is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.4 IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Taltz inhibits the release of pro-inflammatory cytokines and chemokines.4
About Moderate to Severe Plaque Psoriasis Psoriasis is a chronic, immune disease that affects the skin.5 It occurs when the immune system sends out faulty signals that speed up the growth cycle of skin cells. Psoriasis affects approximately 125 million people worldwide, approximately 20 percent of whom have moderate to severe plaque psoriasis.5,6 The most common form of psoriasis, plaque psoriasis, appears as raised, red patches covered with a silvery white buildup of dead skin cells.5 Patients with plaque psoriasis often have other serious health conditions, such as diabetes and heart disease and experience negative impact on their quality of life.5
About the Phase 3 Pediatric Study This study is a Phase 3, multicenter, randomized, double-blinded, placebo controlled study to evaluate safety, tolerability and efficacy of Taltz in patients from 6 to <18 years of age with moderate to severe plaque psoriasis. The co-primary endpoints of the study were the proportion of patients achieving a 75 percent improvement from baseline on their Psoriasis Area and Severity Index score (PASI 75) and a static Physician's Global Assessment of clear or almost clear skin (sPGA 0,1) at Week 12. Key secondary endpoints included the proportion of patients achieving PASI 90, sPGA 0 and PASI 100 at Week 12, and at least a four-point improvement in Itch numeric rating scale (Itch NRS 4) among patients with baseline Itch NRS 4 at Week 12, as well as PASI 75 and sPGA 0,1 at Week 4. The proportion of patients achieving 0 or 1 on the Children's Dermatology Life Quality Index (CDLQI, patients 6 to 16 years old) or DLQI (patients 17 years old) at Week 12 was also evaluated.
About Lilly in DermatologyBy following the science through unchartered territory, we continue Lilly's legacy of delivering innovative medicines that address unmet needs and have significant impacts on people's lives around the world. Skin-related diseases are more than skin deep. We understand the devastating impact this can have on people's lives. At Lilly, we are relentlessly pursuing a robust dermatology pipeline to provide innovative, patient-centered solutions so patients with skin-related diseases can aspire to live life without limitations.
About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a potential treatment for pediatric patients with moderate to severe plaque psoriasis, and reflects Lilly's current belief. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that future study results will be consistent with the results to date, that Taltz will receive additional regulatory approvals, or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertake no duty to update forward-looking statements to reflect events after the date of this release.
1 Data on file. Lilly USA, LLC. TAL20171211A.2 Data on file. Lilly USA, LLC. DOF-IX-US-0019.3 Mease P, Roussou E, Burmester GR, et al. Safety of ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials. Arth Care Res. 2018 (Epub). doi:10.1002/acr.23738.4 Taltz Prescribing Information, 2019.5 Psoriasis media kit. National Psoriasis Foundation website. https://www.psoriasis.org/sites/default/files/for-media/MediaKit.pdf. Accessed September, 2019.6 Skin conditions by the numbers. American Academy of Dermatology website. https://www.aad.org/media/stats/conditions/skin-conditions-by-the-numbers. Accessed September, 2019.
SOURCE Eli Lilly and Company
Go here to see the original:
- Opinion: People with disabilities don't need eugenics to improve - UI The Daily Iowan - March 16th, 2020
- The right has perfected making people expendable but a coronavirus recession will take it further than ever - The Independent - March 16th, 2020
- Assistant professor says he's been fired because he dared to talk about human population variation - Inside Higher Ed - March 16th, 2020
- Iain Macwhirter: Herd immunity does not mean the Government is trying to kill old people - HeraldScotland - March 16th, 2020
- Wendy Vogel on art and abortion - Artforum - March 16th, 2020
- Full Sixth Circuit Takes Up Ohio Ban on Selective Abortions - Courthouse News Service - March 16th, 2020
- Will This Years Census Be the Last? - The New Yorker - March 16th, 2020
- Eugenics - HISTORY - March 14th, 2020
- Introduction to Eugenics - Genetics Generation - March 14th, 2020
- Boris Johnson cares more about the economy than he does about human lives - The Canary - March 14th, 2020
- The World Changed Its Approach to Health After the 1918 Flu. Will It After The COVID-19 Outbreak? - TIME - March 14th, 2020
- The Morality Of Eugenics - New University - March 4th, 2020
- Eugenics and Scientific Racism - Slugger O'Toole - March 4th, 2020
- The history of time capsules has a dark side linked to eugenics. But their future is brighter - ABC News - March 4th, 2020
- Prejudice against Downs Syndrome is a form of eugenics Brian Wilson - The Scotsman - March 4th, 2020
- S. Craig Zahler and the Art of the Podcast - Filmmaker Magazine - March 4th, 2020
- Dumbarton MP critical of Boris Johnson as he tells of brother who died from cerebral palsy - The Dumbarton and Vale of Leven Reporter - March 4th, 2020
- Fakebook and the Big Data manipulators - Pressenza International Press Agency - March 4th, 2020
- Resignation of UK Government Adviser Sparks Controversy Over Link Between Race and IQ - The National Interest Online - March 4th, 2020
- A new view of eugenics shows its ties to the slavery era - Daily Northwestern - February 12th, 2020
- The Dangers In Nationalizing Health Care - Forbes - February 12th, 2020
- It Was Never About Overpopulation - Psuvanguard.com - February 12th, 2020
- Universities must share their oppressive pasts - University World News - January 30th, 2020
- The Talented Mr. Epstein - The American Conservative - January 30th, 2020
- Anti-Semitism preceded Auschwitz and outlived it - The Boston Globe - January 30th, 2020
- Genetic risk scores open a host of concerns and implications - The Daily Cardinal - January 30th, 2020
- Margaret Sanger Is a Hero to the Left. Here's Her History of Ugly Views. - Daily Signal - January 30th, 2020
- Editorial: Lt. Gov. Forest -- Embrace the truth. Stop spreading divisive falsehoods - WRAL.com - January 30th, 2020
- Mengele was a monster and a product of his time - Catholic Herald Online - January 30th, 2020
- eugenics | Description, History, & Modern Eugenics ... - December 27th, 2019
- There's A New Problematic Dating Trend, One Based On DNA Matching - HuffPost India - December 27th, 2019
- Backstory 2019: What Seven Days Writers Didn't Tell You the First Time Around - Seven Days - December 27th, 2019
- Scandal of The Tinker Experiment: demands for apology over Scotland's treatment of gypsy travellers - HeraldScotland - December 27th, 2019
- A year of more Netflix progress - The Irish Catholic - December 26th, 2019
- Eugenics Is Influencing Dating Apps and Other Forms of Tech - Wear Your Voice - December 13th, 2019
- CVTC eugenics victims: 'I always wanted children and never could have them' - Lynchburg News and Advance - December 13th, 2019
- What to Read During the Holiday Break - Georgia Tech News Center - December 13th, 2019
- An Oregon Couple Can Get Their Kids Back From Foster Care. But Many Disabled Parents Don't Get That Chance. - Rewire.News - December 13th, 2019
- Even Taylor Swift Can't Escape 'When Will You Have Kids?' - The Daily Beast - December 13th, 2019
- 'Targeted for Abortion Simply Because They May Have Down Syndrome': PA Gov. Blocks Anti-Eugenics Bill - CBN News - November 27th, 2019
- Book review - "The Guarded Gate: Bigotry, Eugenics, and the Law that kept Two Generations of Jews, Italians, and Other European Immigrants out of... - November 27th, 2019
- Does Your Dog Actually Love You? - The Cut - November 27th, 2019
- Genetically Modified Babies Are Ethically OK - Reason - November 27th, 2019
- Reefer Madness And Seduction Of The Innocent Are Now The Anti-Vaping M.O. - Science 2.0 - November 27th, 2019
- Samanthas Journey Into the Alt-Right, and Back - The New Yorker - November 27th, 2019
- Renowned scientists address ethics, 'twin scientific revolutions' of AI and CRISPR - The Stanford Daily - November 27th, 2019
- Stephen Miller's white supremacy is no surprise but it raises the stakes on impeachment and 2020 - Salon - November 27th, 2019
- When DAFs Belie the Community in Community Foundation - Non Profit News - Nonprofit Quarterly - November 27th, 2019
- Indiana University Provost: The First Amendment says we can't fire our notorious bigot professor, so here's what we're doing instead - Boing Boing - November 27th, 2019
- At least we've on from eugenics...maybe - The Irish Catholic - October 23rd, 2019
- New Governor Addresses Piney Situation - By THOMAS P. FARNER - The SandPaper - October 23rd, 2019
- Universities must stop covering up racism in order to protect their own reputations - The Guardian - October 23rd, 2019
- Trump Makes Startling Statement: 'We've Taken Control of the Oil in the Middle East US Has Control of That' - The New Civil Rights Movement - October 23rd, 2019
- The Climate Change Solution Scientists Have Been Overlooking - Mother Jones - October 16th, 2019
- Eugenics: The Scientific Scandal That Helped Hitler Murder 300,000 Disabled People - Newsweek - October 16th, 2019
- What's on TV tonight: The Met investigates London's drugs gangs, and celebrities head to the First Dates Hotel - iNews - October 16th, 2019
- Selling Babies, Trading Wives - By THOMAS P. FARNER - The SandPaper - October 16th, 2019
- AbbVie Announces New Data from its Dermatology Portfolio and Pipeline at the 28th European Academy of Dermatology and Venereology (EADV) Congress -... - October 13th, 2019
- Scots psoriasis sufferer opens up on how skin condition can affect mental health and leave her not wanting to - The Scottish Sun - October 13th, 2019
- Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology... - October 13th, 2019
- Public awareness on psoriasis increasing: health expert - pna.gov.ph - October 13th, 2019
- IL-41 Levels Elevated in Synovium of Patients With Psoriatic Arthritis - Rheumatology Advisor - October 13th, 2019
- Novartis data show Cosentyx treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and wit... - October 13th, 2019
- New Guelph exhibit reveals history of eugenics education in Ontario - CBC.ca - October 1st, 2019
- Playing God, Ungodly? - Times of India - October 1st, 2019
- Alderman Library in midst of removing 1.7 million books, other items - The Daily Progress - October 1st, 2019
- TV guide: 18 of the best shows to watch this week - The Irish Times - October 1st, 2019
- Hillary Clinton proves impeaching Trump is all about protecting abortion - Lifesite - October 1st, 2019
- Toby Young apologises for accusing Hammond of antisemitism - The Guardian - October 1st, 2019
- Panelists Discuss Technology and Race at Harvard IOP Event | News - Harvard Crimson - October 1st, 2019
- Trump Attacks Obama, Hillary, Biden, and Supports Putin in Off-the-Rails Press Conference With Ukraine President - The New Civil Rights Movement - October 1st, 2019
- Questioning the Truth behind 'Climate Catastrophe' - Alameda Sun - October 1st, 2019
- My father was IBM's first black software engineer. The racism he fought persists in the high-tech world today - Los Angeles Times - September 27th, 2019
- French bishops oppose medically assisted procreation for single moms, lesbians - Crux: Covering all things Catholic - September 27th, 2019
- Not A Unique Case: 87-Year-Old Murdered Disabled Grandson With Overdose - Forbes - September 27th, 2019
- Republic of Lies: the rise of conspiratorial thinking and the actual conspiracies that fuel it - Boing Boing - September 27th, 2019
- Forget Mensa! All Hail the Low IQ - WIRED - September 27th, 2019
- Ripple Price Forecast: XRP vs SWIFT, SEC Updates, and More - May 25th, 2019
- Cryptocurrency News: This Week on Bitfinex, Tether, Coinbase, & More - May 25th, 2019
- Cryptocurrency News: Bitcoin ETFs, Andreessen Horowitz, and Contradictions in Crypto - May 25th, 2019